Regulatory press release

Cinclus Pharma's Nomination Committee for the 2026 Annual General Meeting appointed

According to the principles for the appointment of the Nomination Committee in Cinclus Pharma Holding AB (publ), the Nomination Committee for the 2026 Annual General Meeting shall be composed of members appointed by the three largest shareholders as of September 30, 2025, along with the Chairman of the Board of Directors.

The composition of the Nomination Committee has now been established, and the company
today announces that the Nomination Committee for the 2026 Annual General Meeting consists
of the following members:

Bita Sehat, appointed by Trill Impact Ventures Pharma 1 AB (Chair of the Nomination Committee)
Karl Tobieson, appointed by Linc AB
Kjell Andersson, appointed by PetoMaj Invest AB
Lennart Hansson, Chairman of the Board, is an acting member of the Nomination Committee.

The shareholders who have appointed members to the Nomination Committee together represent approximately 17.4 percent of the votes in Cinclus Pharma Holding AB (publ) as of September 30, 2025.

Cinclus Pharma Holding AB (publ)’s Annual General Meeting will be held on Thursday May 21, 2026.

The Nomination Committee shall submit proposals for resolution by the 2026 Annual General Meeting pertaining to the election of Chairman of the Meeting, fees and composition of the Board, auditors’ fees and the election of auditors and, if necessary, proposals for changes in the instruction to the Nomination Committee. The Nomination Committee’s proposals will be presented in the Notice to the 2026 Annual General Meeting and on Cinclus Pharma’s website, www.cincluspharma.com.

Shareholders wishing to submit proposals to the Nomination Committee can do so by sending an e-mail to cincluspharma.valberedning@vinge.se (subject “Nomination Committee”) or by letter posted to Cinclus Pharma Holding AB (publ), Attn: CFO Maria Engström, Kungsbron 1, SE-111 22, Stockholm, Sweden.

Proposals should, in order to be timely assessed by the Nomination Committee, be submitted no later than February 28, 2026.

About Cinclus Pharma

Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. The first Phase III study commenced in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com.